RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-25 season, according to ...

The CDC's newly rebuilt Advisory Committee on Immunization Practices (ACIP) took aim Thursday at a mercury-based preservative ...

Moderna said its experimental influenza vaccine showed superior efficacy compared with a licensed standard-dose seasonal flu ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

"The severity of this past flu season underscores the need for more effective vaccines." Moderna cited data from the Centers for Disease Control and Prevention showing that seasonal flu-related ...

The vaccine panel hand-selected by health secretary and anti-vaccine advocate Robert F. Kennedy Jr. on Thursday voted ...

Moderna's messenger RNA flu vaccine candidate has shown has shown positive results in a late-stage trial. The biotechnology company said Monday its seasonal influenza vaccine candidate, mRNA-1010, ...

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

While respiratory illnesses such as flu and cough affect Ugandans year-round, researchers have identified specific months ...